Maraviroc in Rheumatoid Arthritis

Exclusion Criteria

• •Diagnosed with any other inflammatory arthritis or a secondary non-inflammatory arthritis that would interfere with disease activity assessments.
• •Subject receiving prior treatment with certain medications for rheumatoid arthritis
• •Tuberculosis and/or a positive tuberculin reaction
• •Significant trauma or major surgery within 2 months
• •History of alcohol and/or drug abuse outside of a defined period of abstinence
• •History of or a finding at screening of postural hypotension
• •Any condition that would affect the oral absorption of the drug
• •History of cancer and in remission less than 3 years or Grade III-IV congestive heart failure
• •Having an infection of human immunodeficiency virus (HIV), Hepatitis B or C or evidence of any active infection
• •Abnormalities of clinical or laboratory assessments completed at the screening visit such as elevated liver enzymes, decreased hemoglobin or an abnormal ECG
• •Having a positive chemokine receptor 5 (CCR5) delta 32 mutation
• •Requiring the use of certain medications
• •Lactating or pregnant women or subjects have reproductive potential unwilling to use an adequate method of birth control
• •Chronic or recent serious or life-threatening infection; severe , progressive and/or uncontrollable renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological disease within 12 weeks of the first dose.